Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(2):110-112; doi:10.1093/jnci/91.2.110
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by McNeil, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McNeil, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 2, 110-112, January 20, 1999
© 1999 Oxford University Press

NEWS

Using HER2 to Choose Chemotherapy in Breast Cancer: Is It Ready for the Clinic?

Caroline McNeil

For the past 5 years, evidence has been mounting that breast tumors with high levels of the protein HER2 respond better to the widely used drug doxorubicin (Adriamycin) than tumors that are HER2 negative. Last month in San Antonio, that pile of data seemed to have reached a critical level, filling much of an afternoon session and spilling into other presentations and poster sessions at the annual Breast Cancer Symposium hosted by the San Antonio Cancer Institute.

With strong data supporting the idea that HER2 levels do correlate with response to doxorubicin and other anthracyclines, the critical question is now the one asked by San Antonio's Peter Ravdin, M.D.: "Are these results ready for clinical application?" For many at the meeting the answer was a cautious yes, tempered mainly the lack of a standardized way . . . [Full Text of this Article]

New Data, Old Trials

Lack of Standards


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
S. Paik, J. Bryant, E. Tan-Chiu, G. Yothers, C. Park, D. L. Wickerham, and N. Wolmark
HER2 and Choice of Adjuvant Chemotherapy for Invasive Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15
J Natl Cancer Inst, December 20, 2000; 92(24): 1991 - 1998.
[Abstract] [Full Text] [PDF]